islatravir
Small moleculeexperimental
Islatravir is an investigational drug for the treatment of HIV infection. It is classified as a nucleoside reverse transcriptase translocation inhibitor (NRTTI). Merck is developing a subdermal drug-eluting implant to administer islatravir. — Wikipedia
Clinical trial activity
29 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
21
Phase 3
13
Phase 4
0
Earliest trial started Sep 17, 2015 (NCT02217904)
Timeline
Indications
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C#C[C@]1(CO)O[C@@H](n2cnc3c(N)nc(F)nc32)C[C@@H]1O- Mol. weight
- 293.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIslatravir ↗
- ChEMBLCHEMBL517231 ↗
Also known as
- mk-8591
- mk-8591
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07086079 | Phase 1 | Sep 26, 2025 | Merck |
| NCT06891066 | Phase 2 | Apr 14, 2025 | Merck |
| NCT06630286 | Phase 3 | Oct 9, 2024 | Gilead Sciences |
| NCT06630299 | Phase 3 | Oct 8, 2024 | Gilead Sciences |
| NCT06811246 | Phase 1 | Feb 7, 2024 | Merck |
| NCT06719570 | Phase 1 | Jan 23, 2024 | Merck |
| NCT06619678 | Phase 1 | Jan 17, 2024 | Merck |
| NCT05766501 | Phase 3 | Mar 17, 2023 | Merck |
| NCT05705349 | Phase 3 | Mar 8, 2023 | Merck |
| NCT05630755 | Phase 3 | Feb 28, 2023 | Merck |
| NCT05631093 | Phase 3 | Feb 20, 2023 | Merck |
| NCT05130086 | Phase 2 | Dec 16, 2021 | Merck |
| NCT05115838 | Phase 2 | Dec 13, 2021 | Merck |
| NCT05052996 | Phase 2 | Oct 5, 2021 | Gilead Sciences, Merck |
| NCT04776252 | Phase 3 | Sep 15, 2021 | Merck |
| NCT04652700 | Phase 3 | Mar 15, 2021 | Merck |
| NCT04564547 | Phase 2 | Mar 9, 2021 | Merck |
| NCT04644029 | Phase 3 | Feb 24, 2021 | Merck |
| NCT04515641 | Phase 1 | Nov 5, 2020 | Merck |
| NCT04568603 | Phase 1 | Oct 16, 2020 | Merck |
Showing 20 of 29 trials
Page 1 / 2
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 27 | 26 | 3 | 2015 |
| Gilead Sciences | For profit | 3 | 3 | 2 | 2021 |
2 organizations
Page 1 / 1